Breast cancer resistance protein (BCRP) affected acquired resistance to gefitinib in a "never-smoked" female patient with advanced non-small cell lung cancer

Lung Cancer

Volumn 58, Issue 2, 2007, Pages 296-299

  Usuda, J ^a   Ohira, T ^a   Suga, Y ^a   Oikawa, T ^a   Ichinose, S ^a   Inoue, T ^a   Ohtani, K ^a   Maehara, S ^a   Imai, K ^a   Kubota, M ^a   Tsunoda, Y ^a   Tsutsui, H ^a   Furukawa, K ^b   Okunaka, T ^c   Sugimoto, Y ^d   Kato, H ^a  

^a TOKYO MEDICAL UNIVERSITY HOSPITAL   (Japan)

^b Tokyo Medical University Ibaraki Medical Center   (Japan)

^c INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^d KEIO UNIVERSITY   (Japan)

Author keywords

Acquired resistance; BCRP; EGFR; Gefitinib

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; METHIONINE; PACLITAXEL; THREONINE;

ADVANCED CANCER; AGED; AMINO ACID SUBSTITUTION; ARTICLE; BRAIN METASTASIS; CANCER RESISTANCE; CASE REPORT; CODON; COUGHING; EXON; FEMALE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHANGITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOKING;

AGED; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; AUTOPSY; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; FATAL OUTCOME; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; NEOPLASM PROTEINS; QUINAZOLINES; RADIOGRAPHY, THORACIC; SMOKING; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34848890376     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.05.019     Document Type: Article

References (11)

1. Garfield D.H. Response to erlotinib after failure to gefitinib in a patient with advanced non-small cell lung carcinoma. J Clin Oncol 24 (2006) 7738-7739
2. Dziadziuszko R., Siemiatkowska A., Limon J., Rzyman W., Jassem J., Bunn A.B., et al. Unusual chemosensitivity of advanced bronchioalveolar carcinoma after gefitinib response and progression: a case report. J Thorac Oncol 2 (2007) 91-92
3. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., et al. EGFR mutation and resistance of non-small-cell lung cancer t gefitinib. N Engl J Med 352 (2005) 786-792
4. Bessho Y., Oguri T., Achiwa H., Muramatsu H., Maeda H., Niimi T., et al. Role of ABCG2 as a biomarker for predicting resistance to CPT-11/SN-38 in lung cancer. Cancer Sci 97 (2006) 192-198
5. Leggas M., Panetta J.C., Zhuang Y., Schuetz J.D., Johnston B., Bai F., et al. Gefitinib modulates the function of multiple ATP-binding cassette transporter in vivo. Cancer Res 66 (2006) 4802-4807
6. Sugimoto Y., Tsukahara S., Ishikawa E., and Mitsuhashi J. Breast cancer resistance protein: molecular target for anticancer drug and pharmacokinetics/pharmacodynamics. Cancer Sci 96 (2005) 457-465
7. Elkind N.B., Szentpetery Z., Apati A., Ozvegy-Laczka C., Varady G., Ujehelly O., et al. Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor iressa (ZD1839, Gefitinib). Cancer Res 65 (2005) 1770-1777
8. Ozvegy-Laczka C., Cserepes J., Elkind N.B., and Sarkadi B. Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters. Drug Resist Updat 8 (2005) 15-26
9. Yanase K., Tsukahara S., Asada S., Ishikawa E., Imai Y., and Sugimoto Y. Gefitinib reverses breast cancer resistance protein-mediated drug resistance. Mol Cancer Ther 3 (2004) 1119-1125
10. Nakamura Y., Oka M., Soda H., Shiozawa K., Yoshikawa M., Itoh A., et al. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Cancer Res 65 (2005) 1541-1546
11. Yoh K., Ishii G., Yokose T., Minegishi Y., Tsuta K., Goto K., et al. Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin Cancer Res 10 (2004) 1691-1697